Amneal: Fourth Quarter Financial Overview

Amneal Pharmaceuticals Reports Fourth-Quarter Profit

Amneal Pharmaceuticals, based in Bridgewater, New Jersey, announced a net profit of $35.1 million for the fourth quarter, marking a turnaround from a loss in the same period last year.

The company’s earnings amounted to $0.11 per share, and after adjusting for special items, earnings reached $0.21 per share.

These results exceeded analysts’ expectations, as the consensus from three analysts polled by Zacks Investment Research predicted earnings of $0.18 per share.

Amneal’s revenue for the quarter was $814.3 million, slightly below the $815.9 million anticipated by analysts surveyed by Zacks.

For the full year, Amneal reported a net income of $72.1 million, or $0.22 per share, returning to profitability. Annual revenue totaled $3.02 billion.

Looking ahead, the company forecasts full-year earnings between $0.93 and $1.03 per share, with projected revenue ranging from $3.05 billion to $3.15 billion.

Since the start of the year, Amneal’s stock price has climbed 15%, and over the past twelve months, shares have surged by 72%.